Arbutus to Join Jefferies Global Healthcare Conference

WARMINSTER, Pa., May 29, 2024 – Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical firm listed on Nasdaq (ABUS), will be participating in the upcoming Jefferies Global Healthcare Conference in New York. This announcement underscores Arbutus’ ongoing commitment to advancing their research and development programs aimed at finding a functional cure for chronic hepatitis B virus (cHBV) infection. The company's management team is scheduled to deliver a formal presentation on June 5, 2024, at 9:30 am ET. They will also engage in one-on-one meetings with investors during the event.

Those interested in the live webcast of the presentation can access it online. Additionally, a replay of the webcast will be available on the Arbutus website for a limited period after the conference.

Arbutus Biopharma Overview

Arbutus Biopharma Corporation, trading under the ticker ABUS on Nasdaq, is a biopharmaceutical company in the clinical stages of development. The firm leverages its extensive expertise in virology to create new therapeutics designed to offer a functional cure for patients suffering from chronic hepatitis B virus (cHBV). The company’s approach focuses on three key areas: suppression of HBV DNA, reduction of surface antigen, and enhancement of HBV-specific immune responses.

The company's promising pipeline features several internally developed, proprietary compounds. Among these is imdusiran (AB-729), an RNA interference (RNAi) therapeutic. Imdusiran has shown significant clinical progress, demonstrating its ability to reduce surface antigen and trigger the HBV-specific immune response. It is currently involved in three Phase 2a combination clinical trials.

Another key compound in Arbutus' pipeline is AB-101, an oral PD-L1 inhibitor. This compound is in the early stages of clinical evaluation, currently undergoing Phase 1a/1b trials.

Arbutus’ strategic focus is on developing therapies with unique mechanisms of action that can be combined to achieve a functional cure for cHBV. The company believes that a multi-faceted approach addressing different aspects of the virus is crucial for success.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!